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Background. Tuberculous meningitis (TBM) is the most devastating form of tuberculosis, yet very little is known about the 
pathophysiology. We hypothesized that the genotype of leukotriene A4 hydrolase (encoded by LTA4H), which determines inflamma-
tory eicosanoid expression, influences intracerebral inflammation, and predicts survival from TBM.
Methods. We characterized the pretreatment clinical and intracerebral inflammatory phenotype and 9-month survival of 764 
adults with TBM. All were genotyped for single-nucleotide polymorphism rs17525495, and inflammatory phenotype was defined by 
cerebrospinal fluid (CSF) leukocyte and cytokine concentrations.
Results. LTA4H genotype predicted survival of human immunodeficiency virus (HIV)–uninfected patients, with TT-genotype 
patients significantly more likely to survive TBM than CC-genotype patients, according to Cox regression analysis (univariate 
P = .040 and multivariable P = .037). HIV-uninfected, TT-genotype patients had high CSF proinflammatory cytokine concentra-
tions, with intermediate and lower concentrations in those with CT and CC genotypes. Increased CSF cytokine concentrations 
correlated with more-severe disease, but patients with low CSF leukocytes and cytokine concentrations were more likely to die from 
TBM. HIV infection independently predicted death due to TBM (hazard ratio, 3.94; 95% confidence interval, 2.79–5.56) and was 
associated with globally increased CSF cytokine concentrations, independent of LTA4H genotype.
Conclusions. LTA4H genotype and HIV infection influence pretreatment inflammatory phenotype and survival from TBM. 
LTA4H genotype may predict adjunctive corticosteroid responsiveness in HIV-uninfected individuals.
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Tuberculous meningitis (TBM) is the most severe form of dis-
ease caused by Mycobacterium tuberculosis [1]. It is characterized 
by a slowly progressive meningoencephalitis with necrotizing, 
granulomatous inflammation predominantly affecting the basal 
meninges. Inflammatory exudates can obstruct the passage of 
cerebrospinal fluid (CSF), leading to hydrocephalus; small and 
medium-sized intracerebral arteries can become inflamed and 
occluded, leading to infarcts; and granulomas may enlarge to form 
tuberculomas, which can cause mass effects and seizures [1, 2]. 
Death or neurological disability occurs in around 50% of cases.
There is a long-standing hypothesis that death from TBM 
results from an excessive intracerebral inflammatory response 
[3]. The corollary of this hypothesis has been that adjunctive 
antiinflammatory treatment with corticosteroids (eg, dexa-
methasone) improves survival, which has been demonstrated 
in predominantly human immunodeficiency virus (HIV)–
uninfected individuals in a small number of trials [4]. Yet how 
corticosteroids improve survival and whether they do so in 
HIV-infected patients remain uncertain [5–7].
We recently identified a common functional promoter 
variant (rs17525495; C/T transition 12  bp upstream of the 
transcription start site) in the gene encoding leukotriene A4 
hydrolase (LTA4H) that appeared to predict survival and dexa-
methasone responsiveness in HIV-uninfected adults with TBM 
[8]. This human candidate gene association study was guided 
by findings in a zebra fish model where LTA4H was found to 
determine the balance of proinflammatory and antiinflamma-
tory eicosanoids in response to mycobacterial infection [8, 9]. 
In humans, LTA4H rs17525495 allele homozygosity (TT and 
CC) was associated with susceptibility to mycobacterial infec-
tion, but the associations involved opposing inflammatory 
states—high inflammation for the TT genotype and low inflam-
mation for the CC genotype [8]. In comparison, heterozygotes 
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(CT) had an intermediate inflammatory response and were 
more likely to survive TBM [8]. In a retrospective study ana-
lyzing HIV-uninfected adults with TBM enrolled into a ran-
domized controlled trial of adjunctive dexamethasone [6], we 
found that the survival benefit of dexamethasone was restricted 
to patients with the hyperinflammatory LTA4H genotype, TT, 
with possible harm suggested in patients with the hypoinflam-
matory genotype, CC [8]. These preliminary findings suggested 
that LTA4H genotype might be a critical determinant of inflam-
mation and consequently of the response to adjunctive antiin-
flammatory treatment.
To investigate these possibilities further and the influence 
of HIV infection on inflammation and survival, we designed a 
prospective study, using a new cohort of 764 Vietnamese adults 
with TBM enrolled into a randomized controlled trial of inten-
sified antituberculosis therapy, the results of which are reported 
elsewhere [10]. All of the patients received adjunctive dexa-
methasone. We have used these carefully characterized patients 
to address the following hypotheses: (1) LTA4H genotype pre-
dicts survival of patients with TBM receiving corticosteroids, (2) 
LTA4H genotype determines pretreatment CSF inflammatory 
phenotype, (3) death from TBM is associated with an inadequate 
intracerebral inflammatory response, and (4) HIV infection is 
associated with an attenuated CSF inflammatory response [11].
METHODS
Participants
As previously described [10], 817 Vietnamese adults (age, 
>17 years) were enrolled into a randomized controlled trial of 
intensified antituberculosis chemotherapy between April 2011 
and June 2014 and were followed for 9  months. Peripheral 
blood and cerebrospinal fluid (CSF) specimens were collected 
on enrollment and stored at −80ºC for later analysis. Fifty-three 
patients were excluded from the current study: 22 did not have 
TBM, 5 did not consent to genetic testing, 9 died early or left 
the study before the blood specimen was collected, and 17 had 
either insufficient DNA concentrations or experienced failure of 
genotyping analysis.
Written informed consent was obtained from each patient 
or from an accompanying relative if the patient could not pro-
vide consent. Protocols were approved by the Oxford Tropical 
Research Ethics Committee in the United Kingdom, the insti-
tutional review boards of the Hospital for Tropical Diseases 
and Pham Ngoc Thach Hospital for Tuberculosis and Lung 
Disease, and the Ethical Committee of the Ministry of Health 
in Vietnam.
Treatment
All patients were randomly allocated to treatment with each 
standard antituberculosis regimen consisting of isoniazid 
(5 mg/kg/day; maximum, 300 mg/day), rifampicin (10 mg/kg/
day), pyrazinamide (25  mg/kg/day; maximum, 2  g/day), and 
ethambutol (20 mg/kg/day; maximum, 1.2 g/day) for 3 months, 
followed by rifampicin and isoniazid at the same doses for a fur-
ther 6 months, or with an intensified regimen that consisted of 
the standard regimen with an additional higher dose of rifam-
picin (15 mg/kg/day) and levofloxacin (20 mg/kg/day) for the 
first 8 weeks of treatment. All patients received adjunctive dexa-
methasone for the first 6–8 weeks of treatment [6], [12]. In HIV-
infected patients, antiretroviral therapy (ART) started prior to 
enrollment was continued unless there were contraindications 
with rifampicin [10]. For ART-naive patients, ART was started 
after 8 weeks of antituberculosis therapy [13].
Clinical and CSF Inflammatory Phenotyping
Detailed clinical assessments were made at baseline and up to 
9  months after randomization. Baseline disease severity was 
assessed by the modified British Medical Research Council 
(BMRC) grading system [14]. An HIV test was performed on all 
patients at enrollment. Concentrations of total and differential 
blood cell counts (including CD4+ T-cell counts in HIV-infected 
patients) and CSF leukocyte counts, lactate levels, glucose lev-
els, and protein levels were measured by standard methods.
A panel of 10 human cytokines was measured in stored CSF 
specimens by Luminex multiplex bead array technology (Bio-
Rad Laboratories, Hercules, CA). The panel consists of inter-
leukin 1β (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, 
interferon γ (IFN-γ), and tumor necrosis factor α (TNF-α). 
Assays were read on the Bio-Plex 200 platform, and the Bio-
Plex Manager software 6.0 was used for bead acquisition and 
analysis. Additional details on the method for cytokine mea-
surement is provided in the Supplementary Materials.
LTA4H Genotyping
LTA4H rs17525495 (C/T) polymorphism was genotyped by 
TaqMan genotyping assay [15] and confirmed by sequenc-
ing. For Taqman genotyping, the assay mixture (LightCycler 
480 Probes Master, Roche) was preloaded with 1 pair of 
primers, to amplify the polymorphic sequence, and 2 fluo-
rescently labeled allele-specific probes (TaqMan predesigned 
SNP genotyping assays, Applied Biosystems), and the fluo-
rescent signals were captured by real-time polymerase chain 
reaction analysis (Light Cycler 480, Roche). For sequencing, 
the primers 5’-TTCACCCATCCCCCAAC-3’ and 5’-GGG 
TGCTGTGAGAGATCTG-3’ were used with the Bigdye 
Terminator v3.1 Cycle Sequence kit (Applied BioSystems) on 
the Genetic Analyzer machine (Applied BioSystems).
Statistical Analysis
Cox regression was used to model the univariable and joint 
effects of predefined risk factors, including LTA4H genotype 
and antituberculosis treatment regimen allocation, on 9-month 
survival. Kaplan–Meier estimates were used to visualize survival 
functions. Comparisons of cytokine concentrations between 
HIV-infected and HIV-uninfected patients were based on the 
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Wilcoxon rank sum test, comparisons of cytokines by disease 
severity or LTA4H genotype were based on a linear trend test 
implemented using robust linear regression, and the effect of 
log-transformed cytokines on survival was assessed via univari-
able Cox regression. For each cytokine analysis, we performed 
resampling-based multiple hypothesis testing to correct for 
multiplicity [16]. Statistical analyses were performed using the 
statistical package R v3.0.1 [17].
RESULTS
Characteristics of the Population
The baseline clinical characteristics of the 764 adults included 
in this study are given in Supplementary Table 1. The majority 
(630 [82.5%]) had BMRC grade 1 or 2 disease severity at enroll-
ment, 325 (42.5%) were infected with HIV, and 395 (51.8%) 
had microbiologically confirmed disease. HIV-infected patients 
were significantly more likely than HIV-uninfected patients 
to be male, to be younger, to weigh less, to have previously 
received tuberculosis treatment, and to have microbiologically 
confirmed TBM. The 9-month case-fatality rate was 27.7% (212 
of 764) overall, 18.9% (83 of 439) among patients without HIV 
infection, and 39.7% (129 of 325) among those with HIV infec-
tion (Supplementary Figure 1). Eighty-nine patients (11.6%) 
had the TT genotype at LTA4H rs17525495, 345 (45.2%) had 
CT, and 330 (43.2%) had CC, and this polymorphism was in 
Hardy-Weinberg equilibrium (P = .995).
Hypothesis 1: LTA4H Genotype Predicts Survival of Patients With TBM 
Receiving Corticosteroids
Our previous findings suggested that dexamethasone increased 
survival among HIV-uninfected adults with TBM who had the 
LTA4H TT genotype but had uncertain and possibly harm-
ful effects in those who had the CT and CC genotypes [8]. In 
this study, intensified antituberculosis chemotherapy was not 
associated with improved survival in all patients, as previously 
reported [10], or in patients stratified by LTA4H genotype 
(Supplementary Figure  1). Univariable analysis indicated that 
LTA4H genotype had no significant impact on survival in all 
patients, but subdivision by HIV status found increased survival 
in HIV-uninfected patients with the TT genotype, compared 
with patients with the other 2 genotypes, as predicted (overall 
likelihood ratio test P = .05; Figure 1 and Table 1). The survival 
rate among CT heterozygotes was more similar to that for CC 
homozygotes than for TT homozygotes. Adjustment for pre-
defined risk factors, including age, weight, BMRC grade, inten-
sified regimen, drug resistance, and CSF leukocyte numbers, 
did not substantially alter the size or strength of the LTA4H gen-
otype association with survival in the HIV-uninfected patients 
(overall likelihood ratio test P = .03; Table 1).
In HIV-infected patients, the effect of LTA4H genotype on 
survival was less pronounced and did not reach statistical sig-
nificance (Figure 1 and Table 1). The evidence that HIV-status 
modified the effect of LTA4H genotype on survival was only 
weak (P for interaction = .168). Table 1 also presents findings of 
multivariable Cox regression analysis of other predefined risk 
factors associated with death from TBM, confirming the prog-
nostic importance of age, weight, HIV infection, BMRC grade, 
drug resistance, and CSF leukocyte numbers.
These findings support the hypothesis that LTA4H genotype 
is associated with survival, independently of other risk factors, 
in HIV-uninfected patients with TBM.
Hypothesis 2: LTA4H Genotype Predicts Inflammatory Phenotype
We surmised that because LTA4H directly affects leukotriene 
B4, a potent neutrophil and macrophage chemoattractant, 
LTA4H genotype might influence the inflammatory phenotype. 
To test this hypothesis, we compared pretreatment CSF leuko-
cyte and cytokine concentrations across LTA4H genotypes in 
Figure 1. Kaplan–Meier survival curves stratified by LTA4H genotype. Survival in all patients with tuberculous meningitis (A), those without human immunodeficiency virus 
(HIV) infection (B), and those with HIV infection (C). In HIV-uninfected patients, case-fatality rates were 7.1% (3 of 42) in those with genotype TT, 21.4% (40 of 187) in those 
with genotype CT, and 18.7% (39 of 209) in those with genotype CC. In HIV-infected patients, case-fatality rates were 34.8% (16 of 46) in those with genotype TT, 42.1% (61 
of 145) in those with genotype CT, and 38.8% (52 of 134) in those with genotype CC. Overall likelihood ratio test for an effect of LTA4H genotype on survival revealed P values 
of .24 for all patients, .05 for HIV-uninfected patients (P = .08 for the effect of TT vs CT, and P = .04 for the effect of TT vs CC), and .87 for HIV-infected patients.
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Figure 1. Kaplan–Meier survival curves stratified by LTA4H genotype. Survival in all patients with tuberculous meningitis (A), those without human immunodeficiency virus 
(HIV) infection (B), and those with HIV infection (C). In HIV-uninfected patients, case-fatality rates were 7.1% (3 of 42) in those with genotype TT, 21.4% (40 of 187) in those 
with genotype CT, and 18.7% (39 of 209) in those with genotype CC. In HIV-infected patients, case-fatality rates were 34.8% (16 of 46) in those with genotype TT, 42.1% (61 
of 145) in those with genotype CT, and 38.8% (52 of 134) in those with genotype CC. Overall likelihood ratio test for an effect of LTA4H genotype on survival revealed P values 
of .24 for all patients, .05 for HIV-uninfected patients (P = .08 for the effect of TT vs CT, and P = .04 for the effect of TT vs CC), and .87 for HIV-infected patients.
both HIV-infected and HIV-uninfected patients. While the TT 
genotype was associated with increased CSF leukocyte counts 
in a previous cohort [8], this association was not found in 
this cohort in either HIV-uninfected patients or HIV-infected 
patients (Supplementary Tables 2–4).
As a more comprehensive readout of inflammation in the 
CSF, we examined cytokine concentrations. In HIV-uninfected 
patients, there was a significant association between LTA4H 
genotype and CSF IL-1β, IL-2, and IL-6 expression, with low 
concentrations of each cytokine in patients with genotype CC, 
intermediate concentrations in those with genotype CT, and 
high concentrations in those with genotype TT (Figure 2A). In 
the zebra fish, LTA4H levels mediate their effects on pathogen-
esis through modulating TNF-α levels [8]. In our cohort, CSF 
TNF-α concentrations had a similar trend as those of the other 
cytokines, but the comparison across LTA4H genotype did not 
reach statistical significance (raw P = .14; multiplicity-adjusted 
P = .49). This may be because dampened signal-to-noise levels 
due to low baseline levels of this more upstream cytokine regu-
lated downstream signaling pathways, causing amplification of 
pathways further downstream [18].
Higher expression of CSF cytokines (ie, IL-1β, IL-2, and IL-6) 
and increased global cytokine expression support the hypothe-
sis that LTA4H genotype influences pretreatment CSF inflam-
matory phenotype, but only for those uninfected with HIV. This 
effect appears to be independent of disease severity, which was 
similar across the genotypes, along with other baseline clinical 
characteristics (Supplementary Tables 2–4). Unlike uninfected 
patients, LTA4H genotype did not affect CSF cytokine concen-
trations in HIV-infected patients (Figure 2B).
Table 1. Univariable Effect of LTA4H on the Hazard of Death and Cox Regression–Based Multivariable Effect of Other Risk Factors on the Hazard of Death, 
Overall and Stratified by Human Immunodeficiency Virus (HIV) Status
Variable
Overall, HR (95% CI) 
(n = 764)a P
HIV Uninfected, HR (95% 
CI) (n = 439)a P
HIV Infected, HR (95% 
CI) (n = 325)a P
LTA4H genotype (univariable effect)b
 TT 1 (reference) 1 (reference) 1 (reference)
 CT 1.26 (.77–2.07) .35 2.83 (.88–9.17) .08 1.14 (.65–2.00) .65
 CC 1.47 (.90–2.39) .12 3.40 (1.05–11.00) .04 1.16 (.67–2.01) .60
Multivariable Cox regression model
 LTA4H genotype (adjusted effect)c
  TT 1 (reference) 1 (reference) 1 (reference)
  CT 1.62 (.95–2.75) .07 2.47 (.76–8.05) .13 1.54 (.78–3.04) .21
  CC 1.65 (.98–2.79) .06 3.51 (1.08–11.43) .037 1.47 (.76–2.85) .25
 Age (per 10-y increase) 1.34 (1.20–1.50) <.0001 1.45 (1.28–1.66) <.0001 1.01 (.73–1.41) .94
 Weight (per 10-kg increase) 0.77 (.64–.92) .005 0.91 (.69–1.18) .47 0.61 (.46–.81) .0007
 HIV infected 3.94 (2.79–5.56) <.0001 … …
 BMRC graded
  1 1 (reference) 1 (reference) 1 (reference)
  2 2.09 (1.44–3.04) .0001 2.71 (1.38–5.3) .004 1.52 (.92–2.54) .11
  3 6.71 (4.54–9.93) <.0001 7.25 (3.52–14.94) <.0001 5.22 (3.13–8.70) <.0001
 Hyperintensive regimen 0.94 (.71–1.25) .69 1.06 (.68–1.68) .79 1.15 (.77–1.72) .50
 ART at enrollment … … 0.65 (.41–1.03) .07
 Resistance category
  No INH or RIF resistance 1 (reference) 1 (reference) 1 (reference)
  INH resistancee 0.99 (.61–1.61) .98 0.55 (.21–1.44) .22 1.00 (.53–1.88) 1.00
  RIF/multidrug resistancef 3.70 (1.84–7.46) .0003 1.90 (.24–14.78) .54 5.78 (2.58–12.92) <.0001
  Unknown resistanceg 1.30 (.91–1.85) .15 0.80 (.43–1.47) .47 1.75 (1.06–2.89) .30
 CSF leukocyte count (per 2-fold 
increase)
0.88 (.83–.93) <.0001 0.85 (.77–.94) .001 0.95 (.87–1.03) .18
 Baseline CD4+ T-cell count (per 100- 
cells/mm3 increase)
… … 0.59 (.40–.87) .007
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CSF, cerebrospinal fluid; HR, hazard ratio; INH, isoniazid; RIF, rifampicin.
aPatients with missing covariates were excluded from the multivariable analysis (26 in the overall group, 14 in the HIV-uninfected group, and 55 in the HIV-infected group, mainly due to 
missing CD4+ T-cell counts).
bOverall likelihood ratio test for significance of LTA4H: P = .24 (overall), P = .05 (HIV uninfected), and P = .87 (HIV infected).
cOverall likelihood ratio test for significance of LTA4H: P = .12 (overall), P = .03 (HIV uninfected), and P = .41 (HIV infected). Variables used for adjustment in multivariable Cox regression are 
as listed in the first column.
dModified British Medical Research Council (BMRC) disease severity criteria are as follows: grade 1, Glasgow coma scale (GCS) score of 15, with no neurologic signs (baseline); grade 2, 
GCS score of 11–14 (or 15, with focal neurologic signs); and grade 3, a GCS score of ≤10.
eResistance to INH, with or without other resistance, but no RIF resistance.
fMultidrug resistance to at least rifampicin RIF and INH, or isolated RIF resistance from culture results.
gPatients for whom no drug resistance results were available.
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Hypothesis 3: Hypoinflammation Is Associated With Death
Given the long-standing hypothesis that excessive intracerebral 
inflammation is strongly linked to death from TBM, we next 
sought to investigate the relationship between pretreatment 
inflammatory CSF phenotype and the risk of death. In this 
trial, all patients received dexamethasone. Taking into account 
the observation from the previous trial that dexamethasone is 
protective in those with a predisposition for a hyperinflamma-
tory response, it is conceivable that, with exposure to cortico-
steroids, patients with an inadequate inflammatory response 
will have worse outcome. In all patients, univariable analysis 
demonstrated that lower CSF leukocyte counts were signifi-
cantly associated with death (P  <  .0001), with median values 
of 59 × 103 cells/mL (interquartile range [IQR], 13–240 × 103 
cells/mL) in those who died and 135  ×  103 cells/mL (IQR, 
48–298 × 103 cells/mL) in survivors. The association was sim-
ilar in HIV-uninfected patients and HIV-infected patients: in 
HIV-uninfected patients, median values in those who died were 
47 × 103 cells/mL (IQR, 12–212 × 103 cells/mL), compared with 
124 × 103 cells/mL (IQR, 48–278 × 103 cells/mL) in survivors 
(P  =  .002); in HIV-infected patients, median values in those 
who died were 77 × 103 cells/mL (IQR, 15–270 × 103 cells/mL), 
compared with 153 × 103 cells/mL (IQR, 46–382 × 103 cells/mL) 
in survivors (P < .0001). In the multivariable analysis, the asso-
ciation only retained significance in HIV-uninfected patients 
(P = .001; Table 1).
Figure 3 presents pretreatment CSF cytokine concentrations 
in those who survived or died, with subgroups defined by HIV 
infection. In HIV-uninfected patients, there was a striking 
association between death and lower cytokine concentrations 
(Figure 3A). In HIV-infected patients, however, cytokine con-
centrations were not different between the 2 groups (Figure 3B).
These data support the notion that poor outcome from TBM, 
in the context of immunosuppressive treatment, is associ-
ated with an inadequate pretreatment inflammatory response 
in HIV-uninfected individuals. Taken together with the 
Figure 2. Cerebrospinal fluid (CSF) levels of cytokine expression, by LTA4H genotype, in human immunodeficiency virus (HIV)–uninfected (A) and HIV-infected (B) patients 
with tuberculous meningitis. Concentrations are in picograms/milliliter for all cytokines except interleukin 6 (IL-6), for which concentrations are in nanograms/milliliter. A, 
Data are for 147 patients with LTA4H genotype CC, 141 with genotype CT, and 16 with genotype TT. B, Data are for 104 patients with LTA4H genotype CC, 87 with genotype 
CT, and 28 with genotype TT. Statistical comparisons were made using a linear trend test corrected for multiple testing across the 10 cytokines. Only P values of ≤ .05 are 
shown. Abbreviations: IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
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associations between LTA4H genotype and both inflammatory 
phenotype and survival, these findings suggest that patients 
with the CC genotype in particular are dying because of an 
inadequate inflammatory response and that adjunctive dexa-
methasone may be harmful to these patients.
These associations could be confounded by disease severity 
at the start of treatment (BMRC grade), a major independent 
determinant of survival from TBM (Table 1). Disease severity 
was not associated with significant differences in CSF leuko-
cyte numbers or types (data not shown). However, elevated 
CSF cytokine concentrations were associated with more-severe 
BMRC grades (Figure  4), especially in HIV-infected patients, 
in whom increasing BMRC grade was significantly associ-
ated with increased concentrations for all measured cytokines 
(Figure 4B). Higher BMRC grade strongly predicted death from 
TBM (Table 1) and was closely linked to more-severe intrace-
rebral inflammation (Figure  4). Yet death was not associated 
with increased CSF cytokine concentrations (Figure 3). Indeed, 
in HIV-uninfected individuals, death was associated with sig-
nificantly decreased CSF cytokine concentrations (Figure 3A). 
This finding supports the idea that another variable, possibly 
LTA4H genotype, influences the relationship between intrace-
rebral inflammation, disease severity, and death.
Hypothesis Four: HIV Infection Is Associated With an Attenuated CSF 
Inflammatory Response
HIV infection is a strong independent predictor of death from 
TBM (Table  1), which may be due to an inadequate immune 
response. We compared the pretreatment CSF cells and cyto-
kine profiles of all HIV-infected and HIV-uninfected patients. 
Intracerebral leukocytes counts were not different, while mean 
neutrophil percentages were higher in HIV-infected patients 
than in HIV-uninfected patients (17% vs 5%; P  <  .0001; 
Supplementary Table 1). HIV infection was associated with an 
unexpected global increase in cytokine expression (Figure 5), 
contradicting our hypothesis. Only the antiinflammatory 
Figure 3. Cerebrospinal fluid (CSF) levels of cytokine expression, by patients outcome, in human immunodeficiency virus (HIV)–uninfected (A) and HIV-infected (B) patients 
with tuberculous meningitis. Concentrations are in picograms/milliliter for all cytokines except interleukin 6 (IL-6), for which concentrations are in nanograms/milliliter. A, 
Data are for 248 patients with an outcome of survival (S) and 56 with an outcome of death (D). B, Data are for 133 patients with an outcome of S and 86 with an outcome of 
D. Statistical comparisons were based on Cox regression models of the univariable effect of (log-transformed) CSF cytokines expression levels on 9-month survival corrected 
for multiple testing across the 10 cytokines. Only P values of ≤ .05 are shown. Abbreviations: IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
1026 • JID 2017:215 (1 April) • Thuong et al
Figure 4. Cerebrospinal fluid (CSF) levels of cytokine expression, by modified British Medical Research Council (BMRC) grade 1, grade 2, and grade 3 disease severity, in 
human immunodeficiency virus (HIV)–uninfected (A) and HIV-infected (B) patients with tuberculous meningitis. Concentrations are in picograms/milliliter for all cytokines 
except interleukin 6 (IL-6), for which concentrations are in nanograms/milliliter. A, Data are for 108 patients with BMRC grade 1 disease severity, 141 with grade 2, and 55 
with grade 3. B, Data are for 98 patients with BMRC grade 1 disease severity, 79 with grade 2, and 42 with grade 3. Statistical comparisons were made using a linear trend 
test corrected for multiple testing across the 10 cytokines. Only P values of ≤ .05 are shown. Abbreviations: IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
Figure 5. Cerebrospinal fluid (CSF) levels of cytokine expression in human immunodeficiency virus (HIV)–infected (I) and HIV-uninfected (UI) patients with tuberculous 
meningitis. Concentrations are in picograms/milliliter for all cytokines except interleukin 6 (IL-6), for which concentrations are in nanograms/milliliter. Statistical comparisons 
between HIV-infected and HIV-uninfected were made by the Mann–Whitney test corrected for multiple testing across the 10 cytokines. Only P values of ≤ .05 are shown. 
Abbreviations: IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
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cytokine IL-10, which inhibits the immune response to M. tuber-
culosis [19], was significantly lower (P = .027) in HIV-infected 
patients, and the CSF ratio of INF-γ to IL-10, an index of proin-
flammatory versus antiinflammatory cytokines, showed a sig-
nificant excess of INF-γ in HIV-infected patients (P <  .0001). 
Pearson correlations between the absolute neutrophil count and 
the 10 log-transformed CSF cytokine concentrations were all 
positive, ranging from 0.08 to 0.47, and all concentrations were 
significantly different from 0 (raw P < .05), except for the IL-13 
concentration (P = .09).
The degree of immune suppression may alter these rela-
tionships and in turn the influence of LTA4H on the inflam-
matory response. CSF cytokine expression profiles were not 
different in those with prior ART (data not shown) but were 
influenced by CD4+ T-cell count. We arbitrarily categorized 
patients on the basis of CD4+ T-cell counts of ≥150 or <150 
cells/µL and compared CSF inflammation between both 
groups and patients without HIV infection. We found that 
patients with the highest level of immunosuppression (ie, 
those with a CD4+ T-cell count of <150) had a significantly 
higher median CSF neutrophil percentage (25%) than patients 
with a CD4+ T-cell count of ≥150 cells/µL (10%; P = .021) and 
patients without HIV infection (5%; P < .0001); patients with 
the highest level of immunosuppression also had significantly 
greater cytokine concentrations than patients in the other 2 
groups (Supplementary Figure 2A). Indeed, the patients with a 
CD4+ T-cell count of ≥150 cells/μL had a similar CSF cytokine 
profile to HIV-uninfected patients, with no significant differ-
ence in concentrations for any cytokine in the multivariable 
analysis.
Forty-four percent of patients (105 of 238)  with a CD4+ 
T-cell count of <150 cells/μL died, compared with 13% (5 of 
39) with a CD4+ T-cell count of ≥150 cells/µL and 19% (83 of 
439)  without HIV infection. LTA4H did not appear to influ-
ence survival in patients with a CD4+ T-cell count of <150 
cells/µL (Supplementary Figure 2B), but in those with a CD4+ 
T-cell count of ≥150 cells/µL (Supplementary Figure 2C), the 
stratified plot by LTA4H genotype was visually similar to the 
corresponding plot for HIV-uninfected patients (Figure  1). 
This analysis was underpowered and exploratory, but these 
data suggest LTA4H may influence intracerebral inflamma-
tion and dexamethasone-associated survival in HIV-infected 
patients with higher CD4+ T-cell counts and warrants further 
investigation.
DISCUSSION
Our previous work suggested that LTA4H genotype may be 
central to the inflammatory response in TBM and might pre-
dict who benefits from adjunctive corticosteroid treatment [8]. 
Here, we extended these original observations in a new cohort 
of 764 prospectively characterized Vietnamese adults with 
TBM, all of whom received corticosteroids.
First, we found that LTA4H genotype influences the survival 
of HIV-uninfected patients with TBM treated with dexametha-
sone (Figure 1 and Table 1). Patients with the TT genotype were 
significantly more likely to survive TBM than those with the CC 
genotype, based on both univariable and multivariable analyses 
(Table 1), which confirms our previous findings. Furthermore, 
we found that patients with the LTA4H TT genotype had high 
CSF proinflammatory cytokine concentrations (IL-1β, IL-2, and 
IL-6), with intermediate and lower concentrations in those with 
the CT and CC genotypes, respectively (Figure 2). This suggests 
that the suppression of inflammation by dexamethasone con-
fers a survival benefit on patients with the TT genotype but may 
be indifferent or even harmful in the other 2 genotype groups.
Second, to test the model in which the best outcomes are 
associated with an intermediate inflammatory response, as 
opposed to either high or low responses, we investigated the 
relationships between disease severity, CSF inflammatory phe-
notype, HIV infection, and survival from TBM. We found that 
increased pretreatment CSF cytokine concentrations correlated 
with more-severe disease. In addition, we observed that, in 
HIV-uninfected patients, death was strongly associated with 
an attenuated inflammatory response. Patients with low pre-
treatment CSF leukocyte and cytokine concentrations were 
more likely to die from TBM. This paradoxical finding may be 
explained by an LTA4H-dependent effect of dexamethasone 
upon survival: patients with the hyperinflammatory TT geno-
type benefit from immune suppression, whereas those with the 
hypoinflammatory CC genotype do not.
HIV infection is well described as an independent predictor 
of death from TBM, but its impact on pathogenesis is poorly 
understood. Surprisingly, death was not associated with high 
or low cytokine expression, but neutrophil and cytokine con-
centrations overall were significantly higher in HIV-infected 
patients than in uninfected patients, with the exception of IL-10. 
Our data confirm previous findings that CSF ratios of INF-γ to 
IL-10 are inclined toward excess INF-γ in HIV-positive patients 
[11] and support the possibility that the alteration skews the 
balance towards a T-helper type 1 response. Moreover, positive 
correlations between CSF neutrophil numbers and cytokine 
concentrations suggest a significant role for neutrophils in the 
immunopathogenesis. In the early stage of disease in HIV-
infected individuals, neutrophils may accumulate at infected 
sites, and overproduction of cytokines (particularly TNF-α) 
may be responsible for tissue damage and contribute to pathol-
ogy [20–23].
LTA4H genotype did not have a significant influence upon 
pretreatment inflammatory phenotype and survival in HIV-
infected patients. Instead, HIV appears to drive a dysregulated 
hyperinflammatory phenotype with very poor outcomes. We 
hypothesized, however, that these effects may be mitigated by 
higher CD4+ T-cell counts. Indeed, we found that patients with 
CD4+ T-cell counts of ≥150 cells/μL had a CSF inflammatory 
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phenotype and survival rate similar to those for HIV-uninfected 
patients and showed a similar albeit nonsignificant link between 
LTA4H genotype and survival.
Previous studies in zebra fish showed that LTA4H regulates 
the balance between proinflammatory and antiinflamma-
tory eicosanoids, namely leukotriene B4 and lipoxin A4 [8, 9]. 
To study the association of LTA4H genotype and concentra-
tions of these 2 metabolites, we measured the metabolites in 
CSF samples from patients with TBM, using enzyme-linked 
immunosorbent assay. Leukotriene B4 levels were undetect-
able in around 50% of samples, and lipoxin A4 assays behaved 
differently on 2 occasions of measurement (data not shown). 
Therefore, no conclusion could be drawn on the regulation of 
leukotriene B4 and lipoxin A4 by LTA4H in the CSF of patients 
with TBM in this study.
In conclusion, these new data suggest that LTA4H and HIV 
influence both pretreatment CSF inflammatory phenotype 
and survival from TBM. We propose a new model for TBM 
pathogenesis whereby both attenuated and excessive inflam-
matory responses are linked to poor survival. This model could 
have profound implications for the use of adjunctive antiin-
flammatory corticosteroids, currently recommended for all 
patients with TBM [24]. Substantial further work is required, 
however, to validate the model and to determine whether cur-
rent therapeutic approaches need revision. In particular, our 
findings need validation in non-Vietnamese populations, the 
mechanism by which LTA4H alters CSF cytokine expression 
and treatment response in patients with TBM needs elucida-
tion, and whether HIV status and LTA4H genotype should be 
used to select patients for adjunctive corticosteroid needs to be 
addressed in randomized controlled trials.
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